
DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target
DENTSPLY SIRONA (XRAY) Analyst Ratings
Bulls say
Dentsply Sirona has demonstrated solid sales performance, particularly in Europe, where reported sales grew by 9.9% and 2.6% on a constant currency basis. Additionally, the Wellspect Healthcare segment has been a significant growth driver, achieving a reported revenue increase of 15.6%, highlighting the company's ability to generate strong volumes across various sales regions. Furthermore, expectations for improved operating expenses as a percentage of revenue suggest a positive outlook for operational efficiency going forward, reinforcing the company's strong market position in the dental equipment and supplies industry.
Bears say
Dentsply Sirona projects a decline in constant currency sales, now estimating a reduction of 4% to 5% compared to an earlier forecast of 2% to 4%. The company's gross margin is expected to decrease by 160 basis points in Q3/25 relative to the same period in 2024, indicating ongoing pressure on profitability, although a slight improvement is anticipated for Q4. Additionally, the company's orthodontics and implants segment is projected to decline by 15%, primarily due to significant headwinds from the Byte business shutdown, contributing to an overall downward adjustment in expected earnings per share and adjusted EBITDA margin for FY/25.
This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.
DENTSPLY SIRONA (XRAY) Analyst Forecast & Price Prediction
Start investing in DENTSPLY SIRONA (XRAY)
Order type
Buy in
Order amount
Est. shares
0 shares